Cyclopentanohydrophenanthrene Ring System Patents (Class 514/26)
  • Patent number: 10688107
    Abstract: A scalable vitamin composition unit dosage adapted to treat a fat-soluble vitamin deficiency in a subject is provided herein, the unit dosage consisting essentially of vitamin D, vitamin E, vitamin K, and vitamin A, wherein the unit dosage is substantially free of additional vitamins and wherein the unit dosage is scalable based on the weight, age, and condition of a subject without inducing toxic effects. Also provided are methods of treating a fat-soluble vitamin deficiency in a subject in need thereof by administering to the subject an effective amount of a unit dosage as described herein.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: June 23, 2020
    Assignee: Callion Pharma, LLC
    Inventor: Konstantinos Andreas Papas
  • Patent number: 10683499
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 16, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 10639341
    Abstract: Herbo-mineral formulation for prevention, treatment and management of Diabetes and method of preparing the same are disclosed herein. The disclosed herbo-mineral formulation includes herb and mineral elements which facilitate in treating Diabetes and Diabetes associated complications. Further the disclosed formulation has been observed to exhibit hypoglycemic, hypolipidemic, and pancreatic cell regenerative properties.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: May 5, 2020
    Assignee: Muniyal Ayurvedic Research Centre
    Inventor: M Vijayabhanu Shetty
  • Patent number: 10624917
    Abstract: The invention includes a method of preventing or treating a toxic liver disease or disorder, such as but not limited to non-alcoholic steatohepatitis (NASH), liver injury associated with or caused by alcohol consumption in a mammal afflicted with NASH, alcoholic hepatitis, drug induced liver injury, primary sclerosing cholangitis, viral hepatitis, liver fibrosis, liver cirrhosis, and other toxic liver conditions, in a subject, such as a mammal. The invention also includes a method of promoting weight loss in a subject, such as a mammal. The invention comprises administering to the subject a therapeutically effective dose of at least one cardiac glycoside or a solvate, salt, prodrug or derivative thereof.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: April 21, 2020
    Assignee: Yale University
    Inventors: Wajahat Mehal, Xinshou Ouyang
  • Patent number: 10576117
    Abstract: Herbo-mineral formulation for prevention, treatment and management of Diabetes and method of preparing the same are disclosed herein. The disclosed herbo-mineral formulation includes herb and mineral elements which facilitate in treating Diabetes and Diabetes associated complications. Further the disclosed formulation has been observed to exhibit hypoglycemic, hypolipidemic, and pancreatic cell regenerative properties.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: March 3, 2020
    Assignee: Muniyal Ayurvedic Research Centre
    Inventor: M Vijayabhanu Shetty
  • Patent number: 10568863
    Abstract: The invention relates to cannabinoids and their isolation and purification and to obtaining them by means of centrifugal partition chromatography.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: February 25, 2020
    Assignee: BIONORICA ETHICS GMBH
    Inventor: Andreas Rutz
  • Patent number: 10487108
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: November 26, 2019
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Patent number: 10391111
    Abstract: Provided are a pharmaceutical composition for preventing or treating cervical cancer including gypenoside LXXV or a pharmaceutically acceptable salt thereof as an active ingredient, a method of preventing or treating cervical cancer including administering the pharmaceutical composition to a subject excluding humans, a health functional food composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient, and a feed composition for preventing or improving cervical cancer including gypenoside LXXV as an active ingredient.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 27, 2019
    Assignee: Intelligent Synthetic Biology Center
    Inventors: Chang Hao Cui, Wan Taek Im, Sun Chang Kim
  • Patent number: 10351589
    Abstract: The invention relates to 3?-ethynyl, 3?-hydroxy, 5?-pregnan-20-oxime, represented by the following structural formula: or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-aminobutyric acid receptor-chloride ionophore (GABAA-R) complex and in the treatment of disorders such as hepatic encephalopathy, Down's syndrome and Alzheimer's disease.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: July 16, 2019
    Assignee: Umecrine Cognition AB
    Inventors: Torbjörn Bäckström, Gianna Ragagnin
  • Patent number: 10335445
    Abstract: The present invention relates to phorbol esters from the seeds of Aquilaria malaccensis by a series of chromatographic processes, and compositions containing these congeners for the treatment of allergic responses.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: July 2, 2019
    Assignee: WE-WIN APPLIED BIO-TECH CO., LTD.
    Inventors: Fang-Rong Chang, Bing-Hung Chen, Hsue-Yin Hsu, Yang-Chang Wu, Chen Hsieh, Hui-Ping Hsieh
  • Patent number: 10265264
    Abstract: Pure saponins and processes for making such saponins are described herein. In addition, cosmetic compositions, such as skin care compositions, comprising such saponins and methods for improving skin health and appearance with such skincare compositions are also described herein.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: April 23, 2019
    Assignee: BIOPROCOL, BIOPROCESOS DE COLOMBIA SAS
    Inventors: German Alfredo Schafer Elejalde, Guillermo Leon Palacio Gonzalez, Carlos Esteban Aristizabal Alzate
  • Patent number: 10238676
    Abstract: The present invention discloses an application of ginsenoside Rg3 in preparing a medicine or product for preventing and treating dementia, and a preparation method thereof, which belong to the fields of medicines and health care products, and its products comprise a topical preparation, oral preparation and injection of the ginsenoside Rg3; and the Rg3 medicine or formulating prepared Rg3 compound medicine is prepared by using a solubilizer, a transdermal agent, a reagent promoting the absorption by penetrating a blood-brain barrier and an extractive, achieving the effect that the medicine penetrates the blood-brain barrier, and is used for preventing and treating dementia.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: March 26, 2019
    Inventor: Li Fu
  • Patent number: 10183000
    Abstract: The current study established that treatment of diabetes using compound 1(2,4-dinitroanilino-benzoic acid), an anthranilic acid derivative, by restoring the functional activities of the pancreas via its insulinotropic action.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 22, 2019
    Inventors: Humera Jahan, Muhammad Iqbal Choudhary, Mehwish Manzoor, Khalid M. Khan, Atta-ur Rahman
  • Patent number: 10149858
    Abstract: The present invention relates to methods for the treatment of migraine headache, cluster headache, tension type headache, trigeminal neuralgia (trigeminal headache) and headache disorders. The methods comprise administration of specific cardiac glycosides: Thevetin A and or Thevetin B to a subject in need thereof a pharmaceutically suitable preparation, in the form of nasal spray and or other modes and methods that will ensure adequate intranasal dosage, a pharmaceutically suitable preparation of the said cardiac glycosides that is sufficient to have the most desirable therapeutic effect when used as a prophylaxis, as a treatment and ameliorating agent of migraine headache and others headache disorders.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: December 11, 2018
    Inventor: Kingsley Yianomah Quartey
  • Patent number: 10137140
    Abstract: This invention relates to a topical composition for prevention and treatment of viral infections.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: November 27, 2018
    Assignee: Dermarc LLC
    Inventors: Linda M. Mahoney, Anne T. Moore, Gary Lee Feiss, Danielle N. Ringhoff
  • Patent number: 10130648
    Abstract: This invention relates to a topical composition for prevention and treatment of viral infections.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: November 20, 2018
    Assignee: Dermarc LLC
    Inventors: Linda M. Mahoney, Anne T. Moore, Gary Lee Feiss, Danielle N. Ringhoff
  • Patent number: 10098987
    Abstract: A coating for an expandable portion of a catheter comprising a hydrophobic matrix and a dispersed phase is disclosed. The dispersed phase comprises a plurality of micro-reservoirs dispersed in the hydrophobic matrix, wherein the plurality of micro-reservoirs comprises a first active agent and a first biodegradable or bioerodable polymer. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: October 16, 2018
    Assignee: M.A. Med Alliance SA
    Inventors: Michael Thomas Ahlering, Ronald Kenichi Yamamoto, Robert John Elicker, Tien Thuy Nguyen, John Edwin Shulze, Jelle Jurjen Zoethout
  • Patent number: 10030243
    Abstract: The present invention relates to an oligonucleotide structure and a method for preparing the same and, more particularly, to an oligonucleotide structure in which a polymer compound is linked to an oligonucleotide via a covalent bond to improve in vivo stability of the oligonucleotide and cellular delivery efficiency of the oligonucleotide; and to a method for preparing the same.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: July 24, 2018
    Assignee: BIONEER CORPORATION
    Inventors: Han Oh Park, Jeiwook Chae, Pyoung Oh Yoon, Boram Han, Gi-Eun Choi, Youngho Ko, Taewoo Kwon, Jae Don Lee, Sun Gi Kim
  • Patent number: 10016495
    Abstract: The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 ?g HA or a low amount such as less than 15 ?g HA.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: July 10, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: William Ripley Ballou, Emmanuel Jules Hanon
  • Patent number: 9987317
    Abstract: The invention relates to cardio-protective agents. In particular, the present invention relates to cardio-protective extracts and fractions thereof prepared from kiwi fruit.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: June 5, 2018
    Assignee: UNIVERSITY OF OSLO
    Inventor: Asim Kanti Duttaroy
  • Patent number: 9969766
    Abstract: The present invention provides 20(R)-ginsenoside Rg3 polyacylated derivatives of the formula (I) and preparation method and anti-tumor application thereof: wherein, R?CH3(CH2)nCO, n=0˜5.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: May 15, 2018
    Inventor: Li Fu
  • Patent number: 9937217
    Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: April 10, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Curtis J. Henrich, Heidi R. Bokesch, Susan E. Bates, Robert W. Robey, Suneet Shukla, Suresh V. Ambudkar, Michael C. Dean, James B. McMahon
  • Patent number: 9938525
    Abstract: The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalized by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: April 10, 2018
    Assignee: NLIFE THERAPEUTICS, S.L.
    Inventors: Maria del Carmen Carmona Orozco, Andrés Pablo Montefeltro, Gabriel G. Alvarado, Analia Bortolozzi, Raquel Revilla-Sanchez
  • Patent number: 9839594
    Abstract: The present invention relates to a skin-moisturizing or wrinkle-improving external composition or cosmetic composition which contains, as an active ingredient, a compound represented by Formula 1, which can be extracted from Anemarrhena asphodeloides Bunge, or a pharmaceutically acceptable salt thereof. The composition prevents skin moisture loss and thus suppresses skin tissue damage induced by UV rays and so has a skin-wrinkle preventing or alleviating effect.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: December 12, 2017
    Assignee: KOREA INSTITUTE OF ORIENTAL MEDICINE
    Inventors: Sung Uk Chae, Mi Young Lee
  • Patent number: 9801894
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: October 31, 2017
    Assignee: Umecrine Cognition AB
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
  • Patent number: 9790253
    Abstract: Provided are a number of compounds structurally related to OSW-1, a natural compound that binds OSBPs. Also provided are pharmaceutical compositions comprising the OSW-1 analogs, as well as methods for use of these OSW-1 analogs, or pharmaceutically acceptable salts, enantiomers, or stereoisomers thereof in the treatment of atherosclerosis. Alzheimer's disease, and cancer, including p21-deficient cancer. Conjugates of OSW-1 analogs with monoclonal antibodies, including monoclonal antibodies targeted to cancer cells, are also provided. Also provided are pharmaceutical compositions comprising the conjugates, as well as methods for use of these conjugates, in the treatment of cancer, including p21-deficient cancer.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: October 17, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Matthew D. Shair, Anthony William George Burgett
  • Patent number: 9770456
    Abstract: The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating impaired neurological functions as well as wound and tissue repair.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: September 26, 2017
    Assignee: Regenera Pharma Ltd.
    Inventors: Zadik Hazan, Andre C. B. Lucassen
  • Patent number: 9597389
    Abstract: The present invention provides an immunogenic influenza composition in a dose volume suitable for human use, comprising an influenza virus antigen or antigenic preparation thereof and an adjuvant composition comprising an oil-in-water emulsion, wherein said oil-in-water emulsion comprises a metabolisable oil at a level of below 11 mg and an emulsifying agent at a level of below 5 mg and optionally a tocol or a sterol at a level of below 12 mg. Suitably the amount of influenza antigen per strain per dose is 15 ?g HA or a low amount such as less than 15 ?g HA.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: March 21, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: William Ripley Ballou, Emmanuel Jules Hanon
  • Patent number: 9585923
    Abstract: The present invention relates to an antioxidant, anti-inflammatory or anti-aging composition containing any one or more of a Taxus cambium- or procambium-derived cell line, an extract thereof, a lysate thereof and a culture medium thereof. The composition according to the present invention has minimized side effects compared to existing antioxidants and anti-inflammatory agents, is involved in intracellular metabolism to reduce intracellular reactive oxygen species, and reduces and induces aging-related signals. Thus, the composition of the preset invention is useful for preventing and delaying aging. In addition, the composition of the present invention has the effect of inhibiting melanogenesis, and thus is useful as a whitening cosmetic composition.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: March 7, 2017
    Assignee: UNHWA CORPORATION
    Inventors: Dae Hee Lee, Eun Kyong Lee, Eun Mi So, Young Woo Jin
  • Patent number: 9573972
    Abstract: The invention relates to compositions for use in animal models of neurodegenerative disease and methods therefor. More particularly, the invention relates to the use of neurotoxic sterol glycosides or neurotoxic glycolipids, or combinations thereof, in animal models of neurodegenerative disease. Neurotoxicity-modulating chromenols can also be used in these animal models in combination with the neurotoxic sterol glycosides or neurotoxic glycolipids, or combinations thereof.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: February 21, 2017
    Assignee: NEURODYN, INC.
    Inventors: Christopher Ariel Shaw, Denis George Kay
  • Patent number: 9546353
    Abstract: The present invention refers to an optimized and defined method for isolation and preservation of precursor cells from human umbilical cord. Besides being reproducible and 100% reliable, in terms of the number of samples processed, the method results in a high and defined number of precursor cells, being the majority obtained after a single adhesion and expansion/multiplication phase ex vivo (thus granting cell phenotype), in a shorter time frame than what was previously described in the state-of-the-art. With this method, it is possible to obtain, in 9 days, after direct freezing of a cell fraction, and after one expansion/multiplication phase ex vivo (end of P0) of the majority of the cells, about 8.6(±0.1)×105 cells/gram of processed umbilical cord. In turn, the characteristics of the cells allow, for example, after 35 days, obtaining an average of 7.7×1015 cells, with precursor phenotype, from 100% of processed umbilical cord samples.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: January 17, 2017
    Assignee: Laboratorio Medinfar-Produtos Farmaceuticos, S.A.
    Inventors: Rita Isabel Ganchas Soares, Maria Constança Baptista Coelho, Jorge Miguel Silva Santos, José Paulo Martins, Vera Alexandra Basto, Pedro Estilita Monteiro Da Cruz, Helder Joaquim Soares Da Cruz
  • Patent number: 9533019
    Abstract: The Calotropis Procera extracts as anti-ulcerative colitis agents include extracts of Calotropis procera obtained by a method comprising the following steps: (a) providing a plant material derived from Calotropis procera, (b) drying the plant material, (c) pulverizing the plant material to provide a fine powder; and (d) extracting the plant material by percolation using 95% aqueous alcohol in a container to obtain an alcoholic extract. A method of treating ulcerative colitis comprises administering a therapeutically effective amount of an alcoholic extract of C. procera to a patient in need thereof.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: January 3, 2017
    Assignee: KING SAUD UNIVERSITY
    Inventors: Amani Shafeek Awaad, Ghada Mohamed Zain, Reham M. El-Meligy, Haya Fahd Alkanhal, Vidya Devenathadesikan Seshadri
  • Patent number: 9511083
    Abstract: Disclosed is the use of a cardiac glycoside to decrease or inhibit the secretion of proinflammatory mediators in the treatment of disease conditions characterized by elevated levels of the proinflammatory mediator. The cardiac glycoside is administered to a mammalian subject in need of such treatment, and dosage is adjusted to the mass of the recipient and the need of the recipient to reduce or inhibit the level of the proinflammatory mediator. The proinflammatory mediators suppressed by the invention include IL-8, IL-6, TNFalpha, ICAM-1, IFNgamma, IL-1-beta, MCP-1, MIP-2, and/or epithelial-mesenchymal-transition (EMT). The cardiac glycoside, digitoxin or oleandrin, can be formulated for administration by injection or as an aerosol administered to the respiratory tract or by being ingested, or as nose drops or nasal spray. According to one use, the digitoxin controls microRNA expression in castration-resistant prostate cancer. The microRNA suppresses IL-8 and IL-6 expression in these cells.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: December 6, 2016
    Inventor: Bette Pollard
  • Patent number: 9492463
    Abstract: Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: November 15, 2016
    Assignee: The University of Toledo
    Inventors: Zi-Jian Xie, Joseph I. Shapiro
  • Patent number: 9494589
    Abstract: A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 15, 2016
    Assignee: Phoenix Biotechnology, Inc.
    Inventors: Otis C. Addington, Peiying Yang, Robert A. Newman
  • Patent number: 9486467
    Abstract: The present invention includes methods for treating or preventing a cancer in a mammal comprising administering to the mammal a therapeutically effective amount of a macrolide antibiotic such as tylosin, erythromycin, oleandomycin, spiramycin, and pharmaceutically acceptable salts and derivatives thereof.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: November 8, 2016
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventor: Rina Rosin-Arbesfeld
  • Patent number: 9480755
    Abstract: The present invention relates to pharmaceutical compositions comprising dapagliflozin and cyclodextrin, preferably (2-hydroxy)propyl-b-cyclodextrin or ?-cyclodextrin, preferably as inclusion complex. The invention further relates to a process for producing said pharmaceutical compositions. Finally, the invention relates to the use of cyclodextrin for producing dapagliflozin-containing dosage forms and to methods of purification of dapagliflozin.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: November 1, 2016
    Assignee: ratiopharm GmbH
    Inventors: István Puskas, Lajos Szente
  • Patent number: 9446147
    Abstract: A sugar-anchor polymer and methods of making and using the same to stabilize a lipid membrane. The sugar-anchor polymer includes a sugar covalently bound to a first anchor and a second anchor wherein the covalent bonds are selected from the group consisting essentially of an oxime bond, a hydrazone bond, an acylhydrazide bond, an aminothioacetal bond, an acetal bond, a thioacetal bond, a dithioacetal bond, a thioether bond and combinations thereof. The method includes reacting a sugar having at least two nucleophilic moieties with at least two anchors, each anchor having at least one electrophilic moiety, to form the polymer. Alternatively, the method includes reacting a sugar having at least two electrophilic moieties with at least two anchors, each anchor having at least one nucleophilic moiety, to form the polymer. The anchors may be lipids or peptides. The sugar-anchor polymers stabilize lipid membranes against serum proteins, dehydration, and cryopreservation.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: September 20, 2016
    Assignee: The Ohio State University
    Inventor: Dennis Bong
  • Patent number: 9399775
    Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: July 26, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin Maier, Satyanarayana Kuchimanchi, Klaus Charisse
  • Patent number: 9320743
    Abstract: Disclosed is the use of 5?-androstane-3?,5,6?-triol in preparing neuroprotective drugs. The compound has significant protective effect against neuron injuries caused by cerebral ischemia, spinal cord ischemia or hypoxia and has no obvious toxic reaction within effective dose thereof.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: April 26, 2016
    Assignee: GUANGZHOU CELLPROTEK PHARMACEUTICAL LTD.
    Inventors: Guangmei Yan, Haiyan Hu, Tiandong Leng, Hanfei Sang, Jingxia Zhang, Pengxin Qiu, Shujia Zhou, Jiesi Chen, Xiuhua You
  • Patent number: 9314492
    Abstract: The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a Panax ginseng cambium-derived cell line including wild ginseng or ginseng; a lysate thereof; an extract thereof; or a culture medium thereof, which are derived from a natural and have minimized side effects compared to the conventional therapeutic drugs, and thus are safe for the human body. Also, they are involved directly in the growth of cancer to induce cancer cell death effectively, and show anticancer activity of inhibiting or reducing the formation of tumor or the growth of tumor.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: April 19, 2016
    Assignees: UNHWA CORPORATION
    Inventors: Young Woo Jin, Eun Kyong Lee
  • Patent number: 9301970
    Abstract: Disclosed are methods and materials for treating or preventing complications due to traumatic injuries using estrogen or derivatives thereof.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: April 5, 2016
    Assignee: The UAB Research Foundation
    Inventors: Irshad H. Chaudry, William J. Hubbard, Zheng Feng Ba
  • Patent number: 9248158
    Abstract: In one embodiment, the present application provides an herbal supplement and method for treating bloating, constipation and/or weight gain in a human subject comprising orally administering to a subject in need thereof an effective amount of the herbal supplement comprising a red quebracho extract. In other embodiments, the supplement may additionally include a triterpenoid saponin, an anti-spasmodic agent, or both.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: February 2, 2016
    Assignee: KBS RESEARCH, LLC
    Inventors: Kenneth Brown, Brandi M. Scott
  • Patent number: 9173851
    Abstract: An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 3, 2015
    Assignee: RAPTOR PHARMACEUTICALS INC.
    Inventors: Kathlene Powell, Ramesh Muttavarapu
  • Patent number: 9161985
    Abstract: A 5?-androstane-3?,5,6?-triol injection and its preparation are disclosed. The injection uses hydroxypropyl-?-cyclodextrin as a solubilizing agent and the active ingredient is present at a weight ratio of 1-20:40-500 to the hydroxypropyl-?-cyclodextrin. The injection may also comprise, by weight, 1-100 parts of at least one isotonic adjusting agent, 0-200 parts of at least one freeze drying filler, and 0-2000 parts of at least one solvent. The preparation method comprises dissolving hydroxypropyl-?-cyclodextrin solution, 5?-androstane-3?,5,6?-triol and at least one additional soluble excipient in water for injection in sequence to obtain a raw injection solution, and subjecting the raw injection solution to decolorization, depyrogenation, filtration and sterilization to obtain the injection, Drying the filtrate yields a solid for injection.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: October 20, 2015
    Assignee: Guangzhou Cellprotek Pharmaceutical Ltd.
    Inventors: Guangmei Yan, Halyan Hu, Jingxia Zhang, Pengxin Qiu, Ling Li, Ning Tian
  • Patent number: 9114102
    Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: August 25, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Curtis J. Henrich, Heidi R. Bokesch, Susan E. Bates, Robert W. Robey, Suneet Shukla, Suresh V. Ambudkar, Michael C. Dean, James B. McMahon
  • Patent number: 9109003
    Abstract: The present invention provides an extraction method for the leaves of Ilex kudingcha C. J. Tseng, and the total saponins from I. kudingcha leaves extracted by using this method, and use of the total saponins in preparing a drug for reducing cholesterol and blood lipids and anti-atherosclerosis. The extraction method comprises the following steps: subjecting I. kudingcha leaves to refluxing extraction with ethanol aqueous solution to obtain an extracted solution; filtering the extracted solution and removing ethanol, and then separating and purifying the solution using a macroporous resin column.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: August 18, 2015
    Assignee: Peking University
    Inventors: Pengfei Tu, Tongmei Zhang, Jiao Zheng, Yong Jiang, Haiyan Zhou, Li Tang, Zhizhong Ma
  • Patent number: 9101575
    Abstract: Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: August 11, 2015
    Assignee: THE UNIVERSITY OF CONNECTICUT
    Inventors: Timothy Hla, Teresa Sanchez, Kevin Patrick Claffey, Ji-Hye Paik
  • Publication number: 20150132409
    Abstract: Agents and devices for affecting nerve function are described. In some variations, a combination of agents, e.g., a cardiac glycoside, an ACE inhibitor, and an NSAID are delivered to affect nerve function. The agent may be delivered locally in a site-specific manner to a targeted nerve or portion of a nerve. For example, the agent may be delivered locally to the renal nerves to impair their function and treat hypertension. One variation of a delivery device includes one or more needle housings supported by a balloon. A delivery needle is slidably disposed within a needle lumen of each needle housing.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 14, 2015
    Inventors: Emily A. Stein, Christina D. Swanson, Michael A. Evans, Kondapavulur T. Venkateswara-Rao
  • Patent number: 9029334
    Abstract: Disclosed is a pharmaceutical composition for the prevention or treatment of metabolic bone diseases, comprising a spinasterol glucoside derivative, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The pharmaceutical composition is effectively useful for preventing or treating metabolic bone diseases.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: May 12, 2015
    Assignee: Lifetree Biotech Co., Ltd.
    Inventors: Chun-Soo Na, Cheol Yi Hong, Hee Kyong Kim, Sun-Young Yoon, Jin-Beom Kim, Hyun-Jung Roh, Hye-Ji Noh, Na-Na Um, Jiyoung Kim, Tae Hoon Lee